Keytruda® in combination with Inlyta® receives US FDA approval for renal cell carcinoma

24 Apr 2019

Written by Johannna Todd, Future Science Group

For clinicians Immuno-oncology Industry and business News Renal Targeted therapies

Merck has recently announced that the US FDA has approved pembrolizumab in combination with axitinib as a first-line treatment for advanced renal cell carcinoma. A pre-specified interim analysis of the pivotal Phase III KEYNOTE-426 trial results were used to support the approval.Merck (NJ, USA)has recently announced that the US FDA has approved Keytruda® (pembrolizumab) in combination with axitinib as a first-line treatment for advanced renal cell carcinoma. A pre-specified interim analysis of the pivotal Phase III KEYNOTE-426 trial results were used to support the approval. The Phase III KEYNOTE-426 trial is a randomized, multi-center, open-label trial enrolling 861 patients who...